Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sensei Biotherapeutics, Inc. filings document a Nasdaq-listed clinical-stage oncology company, its common stock, and its disclosure obligations around pipeline development, operating results, governance, and capital structure. Material-event reports cover financial results, Regulation FD disclosures, board composition and compensation arrangements, and the completed acquisition of Faeth Therapeutics, including acquired-business financial statements and pro forma combined financial information.
Proxy and governance filings describe shareholder voting matters, director and board matters, equity compensation, preferred stock conversion-related disclosures, authorized-share matters, material agreements, and other capital-structure topics. The filing record also reflects clinical and regulatory disclosure categories for PIKTOR and solnerstotug within the company’s oncology development business.
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock. The option covers 166,435 underlying shares at an exercise price of $29.37 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments thereafter, so the option is fully vested by March 11, 2030, subject to his continuous service with the company.
Faeth Therapeutics, Inc. filed an initial ownership report for its Chief Financial Officer, Brian C. Stephenson, showing a stock option to purchase common stock. The option covers 166,435 underlying shares at an exercise price of $29.37 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on March 11, 2027. The remaining shares vest in 36 equal monthly installments thereafter, so the option is fully vested by March 11, 2030, subject to his continuous service with the company.
Faeth Therapeutics, Inc. shareholders Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen reported beneficial ownership stakes in the company via a joint Schedule 13G filing. The filing lists 2,020,103 shares (7.8%) for Suvretta and Mr. Cowen and 1,722,652 shares (6.7%) for Averill, based on 25,778,754 shares outstanding as of June 15, 2026. The filing states these securities are directly owned by advisory clients of Suvretta Capital, that Mr. Cowen is the control person and managing member of Suvretta, and that a joint filing agreement and control-person identification exhibit are attached.
Faeth Therapeutics, Inc. shareholders Suvretta Capital Management, LLC, Averill Master Fund, Ltd. and Aaron Cowen reported beneficial ownership stakes in the company via a joint Schedule 13G filing. The filing lists 2,020,103 shares (7.8%) for Suvretta and Mr. Cowen and 1,722,652 shares (6.7%) for Averill, based on 25,778,754 shares outstanding as of June 15, 2026. The filing states these securities are directly owned by advisory clients of Suvretta Capital, that Mr. Cowen is the control person and managing member of Suvretta, and that a joint filing agreement and control-person identification exhibit are attached.
Faeth Therapeutics: S2G Investments, LLC reports beneficial ownership of 2,575,401 shares of common stock, equal to 9.99% of the class as of June 15, 2026. The filing states these shares reflect conversion on June 15, 2026 of Series B Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, and that 25,778,754 shares outstanding is the denominator used for the percentage. The filer also holds 344.271 shares of Series B Preferred (approximately 344,271 common shares on an as‑converted basis) that are not deemed beneficially owned due to a Beneficial Ownership Limitation the reporting person elected at 9.99%.
Faeth Therapeutics: S2G Investments, LLC reports beneficial ownership of 2,575,401 shares of common stock, equal to 9.99% of the class as of June 15, 2026. The filing states these shares reflect conversion on June 15, 2026 of Series B Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, and that 25,778,754 shares outstanding is the denominator used for the percentage. The filer also holds 344.271 shares of Series B Preferred (approximately 344,271 common shares on an as‑converted basis) that are not deemed beneficially owned due to a Beneficial Ownership Limitation the reporting person elected at 9.99%.
Faeth Therapeutics, Inc. established an at-the-market stock offering program that allows it to sell common stock with an aggregate offering price of up to $150,000,000 through TD Securities (USA) LLC under a new Sales Agreement. The agent will earn a commission of up to 3.0% on shares sold.
The company also reported that on June 15, 2026, 24,435.594 shares of its Series B Non-Voting Convertible Preferred Stock automatically converted into 24,435,594 shares of common stock, resulting in 25,778,754 shares of common stock outstanding as of that date.
Faeth Therapeutics, Inc. filed a shelf registration and prospectus supplement to offer up to $150,000,000 of common stock under a sales agreement with TD Securities (USA) LLC (TD Cowen) as an at-the-market program. Shares may be sold from time to time on Nasdaq at market prices and the company will receive net proceeds from sales.
The prospectus describes the securities that may be offered under the base shelf (common stock, preferred stock, debt securities and warrants), notes that PIKTOR is in ongoing clinical trials with topline Phase 2 data anticipated by year-end 2026, and discloses corporate and charter details including an outstanding Series B Non-Voting Convertible Preferred Stock balance of 501.899 shares convertible at 1,000 common shares per preferred share.
Sensei Biotherapeutics, Inc. director Saira Ramasastry received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $13.00 per share and expire on June 11, 2036.
The options vest in 36 equal monthly installments over three years, so they are fully vested by June 12, 2029, as long as she continues serving with the company. After this grant, she holds options for 25,000 shares directly.
Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock. He acquired 761,428 shares of Common Stock through the conversion of 761.428 shares of Series B Preferred Stock, which are convertible into 1,000 common shares each with no expiration date. The Series B Preferred Stock had been issued as consideration when Faeth Holdings Therapeutics, Inc. common stock was converted into the right to receive these preferred shares at the closing of a multi‑step merger involving Faeth and its holding entities.
Sensei Biotherapeutics, Inc. director Saira Ramasastry reported existing derivative holdings in the form of employee stock options linked to the company’s common stock. One option covers 5,929 underlying shares at an exercise price of $5.22 per share and expires on May 10, 2034.
A second option covers 8,718 underlying shares at an exercise price of $1.16 per share and expires on January 24, 2036. Footnotes explain these options were received in exchange for prior Faeth-related stock options pursuant to a February 17, 2026 Agreement and Plan of Merger.
Sensei Biotherapeutics director Stephen M. Hahn reported acquiring common shares through a preferred stock conversion and receiving a new stock option award. On June 15, 2026, 44,763 shares of Common Stock were acquired upon the conversion of 44.763 shares of Series B Preferred Stock, leaving him with 44,763 common shares directly owned.
Separately, on June 12, 2026, Hahn received a stock option for 25,000 shares of Common Stock at an exercise price of $13.00 per share. This option vests in 36 equal monthly installments and is expected to be fully vested by June 12, 2029, subject to his continued service with the company.
Sensei Biotherapeutics, Inc. director Stephen M. Hahn filed an initial ownership report on Form 3. The filing shows his beneficial ownership of Series B Preferred Stock, which is a convertible security linked to the company’s common stock.
Each share of Series B Preferred Stock is convertible into 1,000 shares of common stock and has no expiration date, giving long-term equity exposure rather than a short-term trading position. The filing notes that this preferred stock position arose in connection with a completed merger involving Faeth Holdings Therapeutics, Inc. and related entities, where HoldCo common stock was converted into the right to receive shares of Sensei’s Series B Preferred Stock.